Newton AH, Danahy DB, Chan MA, Benedict SH. Timely blockade of ICAM-1.LFA-1 interaction prevents disease onset in a mouse model of emphysema.
Immunotherapy 2015;
7:621-9. [PMID:
26098520 DOI:
10.2217/imt.15.31]
[Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
AIM
It is becoming apparent that emphysema is partly driven by self-reactive T cells inducing inflammatory damage. Thus, T cells become targets for therapy similar to other autoimmune diseases. Costimulatory blockade therapy targets disease-specific T cells, rendering them ineffective by blocking a necessary costimulatory event on the T-cell surface. This therapy is tested here in mouse emphysema.
MATERIALS & METHODS
Peptides representing contact domains of counter receptors LFA-1 and ICAM-1 were used as blockade therapy in elastase-induced emphysema.
RESULTS
When administered during the first week after disease induction, blockade prevented lung destruction, reduced leukocyte infiltration and inhibited the decrease in T-cell CD4:CD8 ratio, also common in human emphysema.
CONCLUSION
Costimulatory blockade therapy can affect the progress of emphysema.
Collapse